Mh. Bailey et al., ANTI-HBC ASSAYS - EVALUATION OF END-POINT SENSITIVITY AND PERFORMANCE, British journal of biomedical science, 51(4), 1994, pp. 341-344
The performance characteristics of eight commercially available anti-H
Bc assays-seven ELISAs and a modified haemagglutination assay-were ass
essed using an eight-sample panel of sera collected from blood donors
representing a cross-section of anti-HBc-positive donors that might be
expected to be encountered in the course of routine screening of bloo
d donations. Endpoint sensitivity was investigated with a view to choo
sing one anti-HBc ELISA for use in a second phase routine donor screen
ing study in parallel with the modified haemagglutination test. The ch
osen anti-HBc ELISA had to be of an acceptable sensitivity level in co
mparison with all the other ELISAs investigated, and the ease of use a
nd overall test time had to be taken into account. With a view to this
, although the Murex assay was by far the most sensitive, the test tim
e with the protocol available at the time was too long and therefore t
he Biokit ELISA was chosen for the second phase.